pcDNA5-FRT-TO-Nsp8-Nsp7-HF_GC3opt
(Plasmid
#157702)
-
Purposemammalian expression of C-terminally His8-Flag tagged SARS-CoV-2 Nsp8-Nsp7 fusion protein under control of a tetracycline-inducible promoter
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 157702 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 * |
* Log in to view industry pricing.
Backbone
-
Vector backbonepcDNA5-FRT-TO
-
Backbone manufacturerThermo Fisher
-
Vector typeMammalian Expression
-
Selectable markersHygromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameNsp8-Nsp7-HF_GC3opt
-
SpeciesSARS-CoV-2
-
Mutationcodon optimized; gene expression was optimized by increasing the GC3 content within codons
-
Entrez GeneORF1ab (a.k.a. GU280_gp01)
-
Tag
/ Fusion Protein
- His8-Flag (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site Unknown (unknown if destroyed)
- 3′ cloning site Unknown (unknown if destroyed)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byGene Art
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pcDNA5-FRT-TO-Nsp8-Nsp7-HF_GC3opt was a gift from David Tollervey (Addgene plasmid # 157702 ; http://n2t.net/addgene:157702 ; RRID:Addgene_157702) -
For your References section:
Integrative vectors for regulated expression of SARS-CoV-2 proteins implicated in RNA metabolism. Bresson S, Robertson N, Sani E, Turowski TW, Shchepachev V, Kompauerova M, Spanos C, Helwak A, Tollervey D. Wellcome Open Res. 2020 Nov 3;5:261. doi: 10.12688/wellcomeopenres.16322.1. eCollection 2020. 10.12688/wellcomeopenres.16322.1 PubMed 33313418